Fig. 3.
Fig. 3. Purification of DC1 and DC2. / Mononuclear cells were enriched for DC by the depletion of CD14+ monocytes and CD19+ B cells, followed by the positive selection of HLA-DR-expressing cells using immunomagnetic beads, as described in “Materials and methods.” HLA-DR+ cells were labeled with anti-CD11c PE, anti-IL-3Rα biotin plus streptavidin TC, and FITC-conjugated antibodies to lineage markers CD3, CD14, CD16, CD19, CD20, CD34, CD56, and IgM. CD11c+, FITC− DC1 (left) and IL-3Rαbright, FITC− DC2 (right) were sorted on a FACSVantage using the gates shown in (A). DC1 and DC2 were reanalyzed after separation for purity assessment (B). Results are representative of more than 10 experiments.

Purification of DC1 and DC2.

Mononuclear cells were enriched for DC by the depletion of CD14+ monocytes and CD19+ B cells, followed by the positive selection of HLA-DR-expressing cells using immunomagnetic beads, as described in “Materials and methods.” HLA-DR+ cells were labeled with anti-CD11c PE, anti-IL-3Rα biotin plus streptavidin TC, and FITC-conjugated antibodies to lineage markers CD3, CD14, CD16, CD19, CD20, CD34, CD56, and IgM. CD11c+, FITC DC1 (left) and IL-3Rαbright, FITC DC2 (right) were sorted on a FACSVantage using the gates shown in (A). DC1 and DC2 were reanalyzed after separation for purity assessment (B). Results are representative of more than 10 experiments.

Close Modal

or Create an Account

Close Modal
Close Modal